SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.3)
Meridian Medical Technologies, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.10 par value
--------------------------------------------------------------------------------
(Title of Class of Securities)
589658103
--------------------------------------------------------------------------------
(CUSIP Number)
Robert G. Foster, 4 Milk Street, Portland, ME 04101 (207) 780-0904
--------------------------------------------------------------------------------
(Name, Address, Telephone Number of Persons Authorized to Receive Notices and
Communications)
April 1, 2002
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
Page 1 of Pages
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON
BioVenture Partners Limited Partnership
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [X]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
Not Applicable
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS [ ]
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
--------------------------------------------------------------------------------
NUMBER OF SHARES 7 SOLE VOTING POWER
BENEFICIALLY OWNED BY EACH
REPORTING PERSON WITH 0
------------------------------------------------
8 SHARED VOTING POWER
48,271
------------------------------------------------
9 SOLE DISPOSITIVE POWER
0
------------------------------------------------
10 SHARED DISPOSITIVE POWER
48,271
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
48,271
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
SHARES* [ ]
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.1%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
PN
--------------------------------------------------------------------------------
Schedule 13D BioVenture Partners Limited Partnership
ITEM 2. IDENTITY AND BACKGROUND
The reporting person's name is BioVenture Partners Limited Partnership, a
Delaware limited partnership. The reporting person's principal business is that
of general partner of two venture capital funds, Commonwealth BioVentures IV
Limited Partnership, a Delaware limited partnership ("Fund IV"), and
Commonwealth BioVentures V Limited Partnership, a Delaware limited partnership
("Fund V"). The general partner of the reporting person is Commonwealth
BioVentures, Inc., a Massachusetts corporation ("CBI"). The President and
principal stockholder of CBI is Robert Foster, a U.S. citizen. The business
address for each of the entities and the individual identified above is 4 Milk
Street, Portland, ME 04101.
During the last five years, none of the entities or the individual
identified in the paragraph above have been (i) convicted in a criminal
proceeding (excluding traffic violations and similar misdemeanors) or (ii) a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding has been or is subject to a
judgment, decree or final order enjoining future violations of, or prohibiting
or mandating activities subject to, federal or state securities laws or finding
any violation with respect to such laws.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
The number of shares of the Issuer's common stock that the reporting person
may be deemed to beneficially own is 48,271 (the "Shares"), representing
approximately 1.1% of the reported outstanding shares of the Issuer's common
stock as of February 28, 2002. By virtue of the relationships described in Item
2 above among the reporting person, Fund IV, Fund V, CBI and Mr. Foster, the
reporting person shares the power to vote and dispose of (i) 10,484 of the
Shares held in the name of Fund IV with Fund IV, CBI and Mr. Foster, (ii) 36,297
of the Shares held in the name of Fund V with Fund V, CBI and Mr. Foster and
(iii) 1,490 of the Shares held in the reporting person's name with CBI and Mr.
Foster. The reporting person ceased to be a beneficial owner of more than 5% of
the Issuer's common stock between November 30, 2001 and February 28, 2002 as a
result of a reported increase in the aggregate number of outstanding shares of
the Issuer's common stock between those two dates.
Fund V, a venture fund, is in its last year of existence and has commenced
liquidating fund investments in contemplation of its termination and winding up
of its business. On April 1, 2002, Fund V distributed to its limited partners an
aggregate of 150,000 shares of the Issuer's common stock registered in Fund V's
name in accordance with the terms of Fund V's limited partnership agreement (the
"Distribution"). The Distribution was effected solely as part of Fund V's
investment liquidation process and was not influenced by or otherwise based upon
the reporting person's evaluation of the Issuer's current or anticipated
business, financial, or stock price performance.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete, and correct.
BIOVENTURE PARTNERS
LIMITED PARTNERSHIP
By: Commonwealth Bioventures, Inc. its
general partner
April 2, 2002 By: /s/ Robert G. Foster,
------------- ---------------------------------
Robert G. Foster, President